The component of the m6A writer complex VIRMA is implicated in aggressive tumor phenotype, DNA damage response and cisplatin resistance in germ cell tumors
Vera Miranda‐Gonçalves(Instituto Português de Oncologia Francisco Gentil), Cármen Jerónimo(Universidade do Porto), Catarina Guimarães‐Teixeira(Instituto Português de Oncologia Francisco Gentil), Christoph Oing(Universität Hamburg), Joaquina Maurício(Instituto Português de Oncologia Francisco Gentil), Daniel Nettersheim(Düsseldorf University Hospital), Rui Henrique(Universidade do Porto), Mariana Cantante(Instituto Português de Oncologia Francisco Gentil), Friedemann Honecker(Ostschweizer Kinderspital), Daniela Barros‐Silva(Instituto Português de Oncologia Francisco Gentil), Rita de Cássia Avellaneda Guimarães(Universidade Federal de Mato Grosso do Sul), Leendert H. J. Looijenga(University Medical Center Utrecht), João Lobo(Universidade do Porto), Isaac Braga(Instituto Português de Oncologia Francisco Gentil)
Cited by 59
Related Papers
Patterns of somatic mutation in human cancer genomes
|Nature|2007|3.1k
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers
|Clinical Chemistry|2008|1.1k
Intragenic ERBB2 kinase mutations in tumours
|Nature|2004|790
Morphological and Immunohistochemical Differences between Gonadal Maturation Delay and Early Germ Cell Neoplasia in Patients with Undervirilization Syndromes
|The Journal of Clinical Endocrinology & Metabolism|2005|196
Integrative epigenetic taxonomy of primary prostate cancer
|Nature Communications|2018|167